- LexaGene (LXG) has signed a statement of work with a major biopharma company
- This is the same biopharma company that purchased one of LexaGene’s MiQLab Systems for automated genetic testing last week
- If the data generated during this validation study meets this biopharma company’s needs, and Lexagene’s technology is adopted for in-process testing, a single manufacturing plant could generate millions of dollars in revenue annually for LexaGene
- Lexagene Holdings Inc. (LXG) is up 21.43 per cent, trading at C$0.17 per share at 11:15 am ET
LexaGene (LXG) has signed a statement of work with a major biopharma company.
This is the same biopharma company that purchased one of LexaGene’s MiQLab Systems for automated genetic testing last week.
LexaGene’s Founder and CEO, Dr. Jack Regan, said the technology validation study outlined within the signed statement of work will provide this biopharma company with much of the data they need to make future decisions in just a few weeks of time.
“This company has agreed to have the validation work done at LexaGene, and they will have a scientist embedded onsite during parts of the study. The biopharma company will provide some bio-reactor samples that are required for the study.”
He added that if the data generated during this validation study meets this biopharma company’s needs and Lexagene’s technology is adopted for in-process testing, he believes a single manufacturing plant would generate millions of dollars in revenue annually for LexaGene. This biopharma company operates many manufacturing plants both domestically and worldwide.
LexaGene is a molecular diagnostics company that has commercialized the MiQLab System for fast and easy detection of pathogens and other molecular markers. The System is designed for on-site usage and uses real-time PCR chemistry.
Lexagene Holdings Inc. (LXG) is up 21.43 per cent, trading at C$0.17 per share at 11:15 am ET.